A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex

Antimicrobial Agents and Chemotherapy · Published 2026-07-13 · DOI 10.1128/aac.01977-25

Free full text

Authors (6)

Arun Kapoor, Ayan K. Ghosh, Michael Forman, Alyza Skaist, Sarah Wheelan, Ravit Arav-Boger

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kapoor, A., Ghosh, A., Forman, M., et al. (2026). A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01977-25

Related articles

• Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage · Expert Opinion on Therapeutic Patents · 2026 · Cites or is cited by this article
• PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• An Achilles' heel for methicillin-resistant Staphylococcus aureus ? Re-evaluating β-lactam susceptibility of MRSA · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• A community-based One Health approach to the pandemic dynamics of Escherichia coli ST131 · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Development of domain-specific probes of Plasmodium falciparum heat shock protein 70-1 · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• NagX, a periplasmic β- N -acetylglucosaminidase, contributes to NagZ-independent β-lactamase expression in Stenotrophomonas maltophilia · Antimicrobial Agents and Chemotherapy · 2026 · Same journal